Noopur S. Raje
#135,844
Most Influential Person Now
Noopur S. Raje's AcademicInfluence.com Rankings
Noopur S. Rajemedical Degrees
Medical
#2353
World Rank
#2772
Historical Rank
Oncology
#138
World Rank
#143
Historical Rank

Noopur S. Rajephilosophy Degrees
Philosophy
#6854
World Rank
#9964
Historical Rank
Logic
#3952
World Rank
#5187
Historical Rank

Download Badge
Medical Philosophy
Noopur S. Raje's Degrees
- Masters Medicine University of Mumbai
- Doctorate Internal Medicine University of Mumbai
Why Is Noopur S. Raje Influential?
(Suggest an Edit or Addition)Noopur S. Raje's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. (2015) (1386)
- Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. (2001) (909)
- Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. (2000) (902)
- Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma (2019) (840)
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. (2010) (813)
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. (2021) (586)
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. (2019) (555)
- Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. (2012) (521)
- Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. (2001) (440)
- Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. (2005) (431)
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. (2007) (395)
- Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. (2009) (347)
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. (2014) (339)
- Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. (2013) (322)
- Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application (2005) (317)
- International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. (2013) (309)
- Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. (2015) (293)
- Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. (2006) (291)
- In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells (2011) (289)
- Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. (2018) (263)
- NCCN clinical practice guidelines in oncology: multiple myeloma. (2009) (260)
- A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. (2009) (257)
- Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. (2008) (248)
- Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (243)
- Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma (2015) (242)
- Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. (2009) (239)
- Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study (2017) (230)
- Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. (2006) (224)
- A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma (2007) (219)
- International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. (2019) (213)
- Thalidomide--a revival story. (1999) (211)
- Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease (2010) (210)
- Latest advances and current challenges in the treatment of multiple myeloma (2012) (206)
- SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. (2009) (203)
- Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (2008) (202)
- Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. (2009) (202)
- A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. (2010) (196)
- SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. (2000) (191)
- The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo (2009) (189)
- BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study (2018) (188)
- Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. (2004) (185)
- Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients (2013) (183)
- Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. (2007) (182)
- Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). (2019) (182)
- A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. (2014) (180)
- Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. (2005) (177)
- Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (2017) (170)
- PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. (2010) (168)
- Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma (2011) (167)
- A randomized trial of maintenance interferon following high‐dose chemotherapy in multiple myeloma: long‐term follow‐up results (1998) (163)
- 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells (2007) (162)
- VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. (2004) (162)
- Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. (2004) (161)
- Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma (2010) (155)
- Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. (2016) (154)
- Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. (2019) (154)
- Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). (2004) (153)
- JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. (2007) (143)
- MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. (2007) (143)
- Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw (2008) (139)
- NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. (2018) (132)
- Neutralizing B-Cell–Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model (2007) (129)
- Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. (2003) (126)
- A Novel Role for CCL3 (MIP-1α) in Myeloma-induced Bone Disease via Osteocalcin Downregulation and Inhibition of Osteoblast Function (2011) (125)
- Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. (2011) (123)
- Genetic interrogation of circulating multiple myeloma cells at single-cell resolution (2016) (121)
- Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. (2018) (120)
- RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells (1999) (117)
- Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. (2009) (115)
- MLN120B, a Novel IκB Kinase β Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo (2006) (114)
- Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells (2007) (112)
- PR‐924, a selective inhibitor of the immunoproteasome subunit LMP‐7, blocks multiple myeloma cell growth both in vitro and in vivo (2011) (111)
- Thalidomide and lenalidomide: Mechanism-based potential drug combinations (2008) (109)
- AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition (2010) (108)
- FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. (2005) (108)
- p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells (2004) (107)
- NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. (2019) (107)
- Cyclin dependent kinases in cancer (2012) (105)
- Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers. (2015) (102)
- Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin (2014) (100)
- Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. (1999) (100)
- High-Dose Zoledronic Acid Impacts Bone Remodeling with Effects on Osteoblastic Lineage and Bone Mechanical Properties (2009) (99)
- Ascorbic acid inhibits antitumor activity of bortezomib in vivo (2009) (98)
- A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma (2018) (97)
- Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? (2019) (95)
- Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results. (2020) (93)
- Ricolinostat (ACY‐1215) induced inhibition of aggresome formation accelerates carfilzomib‐induced multiple myeloma cell death (2015) (87)
- Regulation of Sclerostin Expression in Multiple Myeloma by Dkk‐1: A Potential Therapeutic Strategy for Myeloma Bone Disease (2016) (85)
- The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival (2015) (83)
- Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma (2004) (81)
- Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. (2011) (80)
- Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. (2009) (80)
- Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. (2010) (79)
- Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors (2018) (78)
- Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. (2021) (78)
- Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study (2008) (77)
- Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. (2000) (77)
- Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy (2017) (77)
- Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib (2009) (76)
- Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. (2018) (75)
- Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. (2000) (74)
- CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. (2000) (71)
- Thalidomide and immunomodulatory drugs as cancer therapy. (2002) (70)
- Immunotherapeutic strategies for the treatment of plasma cell malignancies. (2000) (69)
- The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. (2011) (68)
- Multiple myeloma, version 1.2013. (2013) (68)
- Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells (2011) (68)
- Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy (2018) (68)
- Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. (2021) (67)
- Multiple Myeloma, version 3.2018: Featured updates to the NCCN guidelines (2018) (67)
- Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment (1997) (66)
- Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease (2014) (66)
- Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. (1999) (66)
- Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations (2015) (65)
- Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma. (2010) (65)
- In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. (2013) (65)
- MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. (2006) (65)
- Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. (1999) (64)
- Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma (2009) (64)
- bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study. (2018) (63)
- Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway (2005) (63)
- A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. (2011) (62)
- NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. (2016) (61)
- Kidney disease associated with plasma cell dyscrasias. (2010) (61)
- Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. (2020) (60)
- A Phase Ib study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. (2019) (59)
- A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C‐VAMP) as induction treatment followed by autografting in previously untreated myeloma (1997) (58)
- SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. (2005) (58)
- Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA Damage1 (2000) (57)
- Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide (2011) (57)
- Targeting IL-17A in Multiple Myeloma: A Potential Novel Therapeutic Approach in Myeloma (2015) (57)
- p38 mitogen‐activated protein kinase inhibitor LY2228820 enhances bortezomib‐induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications (2008) (57)
- Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. (2015) (56)
- Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes (2020) (56)
- Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. (2021) (56)
- Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. (2007) (55)
- Neurological manifestations of Waldenström macroglobulinemia (2008) (55)
- Current developments in immunotherapy in the treatment of multiple myeloma (2018) (55)
- Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone (1999) (54)
- Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. (2005) (53)
- First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results. (2017) (53)
- How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma (2019) (53)
- Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with amyloid deposition: a clinicopathologic case series. (2012) (53)
- Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma (2017) (53)
- Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial (2018) (52)
- BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen‐activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth (2007) (52)
- Management of bone disease in multiple myeloma (2014) (49)
- Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. (2022) (49)
- Isolation and characterization of human multiple myeloma cell enriched populations. (2000) (49)
- Case records of the Massachusetts General Hospital. Case 9-2008. A 65-year-old woman with a nonhealing ulcer of the jaw. (2008) (48)
- Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy (2019) (48)
- A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. (2010) (48)
- Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-β inhibitors (2005) (48)
- Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study (2020) (48)
- Small Molecule Multi-Targeted Kinase Inhibitor RGB-286638 Triggers P53-Dependent and -Independent Anti-Multiple Myeloma Activity through Inhibition of Transcriptional CDKs (2013) (48)
- Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study. (2008) (47)
- Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial (2016) (47)
- Myeloma and Bone Disease (2017) (46)
- The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG) (2019) (45)
- Novel therapies in the treatment of multiple myeloma. (2009) (45)
- Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) (2016) (44)
- Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma (2020) (44)
- Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. (2012) (43)
- Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy (2013) (43)
- Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma (2007) (43)
- Novel therapeutic targets for multiple myeloma. (2010) (42)
- Panobinostat and Multiple Myeloma in 2018 (2018) (40)
- Novel Bone-Targeted Strategies in Oncology (2010) (40)
- Bone Marker–Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study (2015) (39)
- An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma. (1996) (39)
- Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study. (2009) (39)
- Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing (2018) (39)
- Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. (2020) (38)
- Role of the RANK/RANKL Pathway in Multiple Myeloma (2018) (38)
- Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study. (2009) (38)
- Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (2019) (38)
- A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma (2008) (38)
- Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue. (1995) (37)
- Phase 2 study of tabalumab, a human anti‐B‐cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma (2017) (37)
- A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity (2014) (37)
- Efficacy of Vemurafenib in Patients With Non–Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study (2019) (36)
- Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy (2012) (36)
- Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs (2005) (35)
- Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide (2014) (35)
- VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). (2014) (34)
- Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients (2012) (34)
- Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study. (2007) (34)
- Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma (2021) (34)
- MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM) (2013) (33)
- In vitro and In vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN 9708 Against Multiple Myeloma Cells (2011) (32)
- ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM) (2013) (32)
- Successful anti‐CD19 CAR T‐cell therapy in HIV‐infected patients with refractory high‐grade B‐cell lymphoma (2019) (32)
- Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib (2008) (32)
- Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma. (2002) (32)
- Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia (2021) (32)
- Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study. (2007) (31)
- Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma (2008) (31)
- Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up (2010) (30)
- Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma (2017) (29)
- The implication of compromised renal function at presentation in myeloma (2001) (29)
- P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells. (2004) (29)
- Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma (2021) (28)
- Kinetics of paraprotein clearance after autografting for multiple myeloma. (1995) (27)
- Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (2020) (27)
- Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma (2018) (27)
- Functional interaction between retinoblastoma protein and stress-activated protein kinase in multiple myeloma cells. (1999) (27)
- Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of β-catenin/TCF pathway (2007) (26)
- A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia (2019) (26)
- Denosumab for the treatment of bone disease in solid tumors and multiple myeloma. (2018) (26)
- PI3K/p110 is a novel therapeutic target in multiple myeloma (2011) (26)
- Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma. (1997) (26)
- Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma (2016) (26)
- Myeloma bone disease: pathogenesis and treatment. (2017) (26)
- Ixazomib for the treatment of multiple myeloma (2018) (25)
- Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma (2014) (25)
- Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-BASKET Study. (2018) (24)
- Bone Anabolic Agents for the Treatment of Multiple Myeloma (2011) (24)
- Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study (2012) (24)
- Monoclonal Antibodies in Multiple Myeloma Come of Age. (2015) (24)
- Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system (1999) (23)
- Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstrom's Macroglobulinemia (2017) (23)
- Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1 (2021) (23)
- Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies (2016) (22)
- Infection analysis in acute lymphoblastic leukemia: a report of 499 consecutive episodes in India. (1994) (22)
- Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. (2015) (22)
- A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma (2018) (22)
- Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma (2006) (22)
- Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study) (2015) (22)
- Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). (2021) (21)
- Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells (2006) (21)
- Plasma Cell Tumors (2003) (21)
- Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins. (2021) (21)
- A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma (2018) (21)
- Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study (2008) (21)
- Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. (2021) (20)
- BCL2 blockade overcomes MCL1 resistance in multiple myeloma (2019) (19)
- Role of Decorin in Multiple Myeloma (MM) Bone Marrow Microenvironment (2013) (19)
- Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study) (2015) (19)
- VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m). (2014) (19)
- Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial (2009) (19)
- The rise of western medicine in India (1996) (18)
- in patients with multiple myeloma Elevated soluble MUC 1 levels and decreased anti-MUC 1 antibody levels (2000) (18)
- AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3β (2008) (18)
- Management of relapsed and relapsed/refractory multiple myeloma. (2011) (18)
- Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM) (2014) (18)
- Advances in supportive care for multiple myeloma. (2014) (18)
- Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma (2016) (17)
- Introduction: the evolving role of bisphosphonate therapy in multiple myeloma. (2000) (17)
- A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America (2018) (17)
- Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. (2021) (17)
- Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study (2020) (17)
- Melanotic neuroectodermal tumor of infancy: Report of a case with ganglionic differentiation (1994) (17)
- Bone Disease in Multiple Myeloma. (2016) (17)
- Pim2 is important for regulating DNA damage response in multiple myeloma cells (2016) (17)
- Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM) (2014) (17)
- Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. (2022) (17)
- Targeting BRAF in multiple myeloma. (2013) (16)
- Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study) (2016) (16)
- In vivo and in vitro cytotoxicity of R‐etodolac with dexamethasone in glucocorticoid‐resistant multiple myeloma cells (2006) (16)
- Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA (2022) (16)
- A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (2014) (15)
- Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma) (2018) (15)
- Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors (2014) (15)
- ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study) (2015) (15)
- Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma (2012) (15)
- Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonates. (2012) (14)
- A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma (2019) (14)
- Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM). (2015) (14)
- New monoclonal antibodies on the horizon in multiple myeloma (2017) (14)
- Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease. (2017) (14)
- Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis (2020) (14)
- Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results. (2009) (14)
- Future Novel Single Agent and Combination Therapies (2009) (13)
- A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005) (2015) (13)
- Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM) (2008) (13)
- Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy. (1996) (13)
- selective HDAC 6 inhibitor , ACY-1215 , in combination with bortezomib in Preclinical activity , pharmacodynamic and pharmacokinetic properties of a (2012) (13)
- Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma (2019) (13)
- RGB 286638, a Novel Multi-Targeted Small Molecule Inhibitor, Induces Multiple Myeloma (MM) Cell Death through Abrogation of CDKDependent and Independent Survival Mechanisms (2008) (13)
- Erratum: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (Leukemia (2008) vol. 22 (1925-1932) 10.1038/leu.2008.174) (2008) (13)
- Value of low-dose whole-body CT in the management of patients with multiple myeloma and precursor states (2018) (13)
- Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study (2015) (12)
- Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma. (2011) (12)
- CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002 (2021) (12)
- Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference (2017) (12)
- Low incidence of CNS relapse with cranial radiotherapy and intrathecal methotrexate in acute lymphoblastic leukemia. (1996) (12)
- Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. (2016) (12)
- Current management and emerging treatment strategies for multiple myeloma. (2019) (11)
- Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma (2016) (11)
- Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM) (2015) (11)
- An International, Randomized, Double Blind Trial Comparing Denosumab With Zoledronic Acid (ZA) for the Treatment of Bone Disease in Patients (Pts) With Newly Diagnosed Multiple Myeloma (2017) (11)
- Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma (2014) (11)
- Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma (2021) (11)
- Introduction: the evolving role of bisphosphonate therapy in multiple myeloma (2000) (11)
- Bisphosphonates and atypical femoral fractures. (2010) (11)
- Case records of the Massachusetts General Hospital. Case 7-2010. A 49-year-old man with peripheral neuropathy and ascites. (2010) (11)
- Effect of the BET Inhibitor, Cpi-0610, Alone and in Combination with Lenalidomide in Multiple Myeloma (2015) (11)
- Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM) (2014) (11)
- Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis (2010) (11)
- High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study. (2009) (11)
- How to Treat High-Risk Myeloma at Diagnosis and Relapse. (2021) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- The mTOR Inhibitor RAD001 (everolimus) Is Active Against Multiple Myeloma Cells In Vitro and in Vivo. (2004) (10)
- Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study (2018) (10)
- Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials (2020) (10)
- PI 3 K / p 110 is a novel therapeutic target in multiple myeloma (2010) (10)
- Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma (2021) (10)
- Phase 1 Study of CART-Ddbcma, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma (2020) (10)
- Combination of the mTOR inhibitor Rapamycin and Revlimid ( CC-5013 ) has synergistic activity in Multiple Myeloma (2004) (10)
- Role of CD34+ cells in engraftment after high-dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue. (1996) (10)
- Management of Relapsed and Relapsed/Refractory Multiple Myeloma (2011) (10)
- Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation. (2017) (10)
- Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy. (2016) (9)
- Elevated soluble MUC 1 levels and decreased anti-MUC 1 antibody levels in patients with multiple myeloma (2000) (9)
- Clinical Grade “SNaPshot” Genetic Mutation Profiling in Multiple Myeloma (2014) (9)
- Comprehensive Genetic Interrogation of Circulating Multiple Myeloma Cells at Single Cell Resolution (2016) (9)
- Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (2015) (9)
- High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial (2017) (9)
- ATRAID regulates the action of nitrogen-containing bisphosphonates on bone (2020) (9)
- A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. (2018) (9)
- The Medical Research Council Myeloma IX trial: the impact on treatment paradigms* (2012) (9)
- Treatment of Smoldering Multiple Myeloma: Ready for Prime Time? (2020) (9)
- Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM) (2010) (9)
- Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma. (1999) (9)
- Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics (2019) (9)
- Sodium fluoride PET imaging as a quantitative pharmacodynamic biomarker for bone homeostasis during anti-DKK1 therapy for multiple myeloma (2017) (9)
- Restoration of Bone Balance Via Activin a Inhibition Results in Anti-Myeloma Activity (2008) (9)
- Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. (2014) (8)
- Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma (2021) (8)
- Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications. (2006) (8)
- Minimal residual disease in multiple myeloma: why, when, where. (2021) (8)
- Clinical trials of bisphosphonates in multiple myeloma. (2012) (8)
- Genetic predisposition for medication-related osteonecrosis of the jaws: a systematic review. (2019) (8)
- Current Treatment Strategies for Multiple Myeloma. (2020) (8)
- Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial. (2013) (7)
- Evaluating results from the multiple myeloma subset of patients treated with denosumab or zoledronic acid (ZA) in a randomized phase III study. (2013) (7)
- Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy (2020) (7)
- Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis (2000) (7)
- Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study (2019) (7)
- Adult acute lymphoblastic leukemia: results of an aggressive regimen in India. (1994) (7)
- Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM) (2017) (7)
- CD 40 activation mediates p 53-dependent cell cycle regulation in human multiple myeloma cell lines (2000) (7)
- Sequencing of nontransplant treatments in multiple myeloma patients with active disease. (2016) (7)
- Monitoring protein synthesis in single live cancer cells. (2016) (7)
- Inhibition of the TGF-β Signaling Pathway in Tumor Cells (2007) (6)
- Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (2008) (6)
- Case records of the Massachusetts General Hospital: Case 29-2011: A 66-year-old woman with cardiac and renal failure. (2011) (6)
- An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma. (2009) (6)
- Psychosocial effects of the relaxation response resiliency program (SMART-3RP) in patients with MGUS and smoldering multiple myeloma: A waitlist controlled randomized clinical trial. (2017) (6)
- Bortezomib Induces Proliferation of Mesenchymal Progenitor Cells and Promotes Differentiation towards Osteoblastic Lineage. (2006) (6)
- Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma (2022) (6)
- Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma – a phase I/II feasibility and tolerance study of 17 patients (2000) (6)
- Targeting Bcl-2 as Therapy for Multiple Myeloma. (2005) (6)
- A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma (2019) (6)
- Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications In Patients with Multiple Myeloma: Interim Analysis Results of the Z-MARK Study (2010) (5)
- Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM). (2022) (5)
- Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA. (2019) (5)
- The Combination of the mTOR Inhibitor Rapamycin and Proteasome Inhibitor Bortezomib Is Synergistic In Vitro in Multiple Myeloma. (2006) (5)
- A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma. (2018) (5)
- Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma (2011) (5)
- MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM). (2013) (5)
- KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation (2022) (5)
- A proto-oncogene BCL 6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells (2010) (5)
- Carfilzomib (CFZ, Kyprolis®), lenalidomide (LEN, Revlimid®), and dexamethasone (DEX) (KRd) combined with autologous stem cell transplant (ASCT) shows improved efficacy compared with KRd without ASCT in newly diagnosed multiple myeloma (NDMM) (2015) (5)
- Arachidonic Acid Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma (2018) (5)
- Promoting Osteoblastogenesis Using a Novel Dkk-1 Neutralizing Antibody in the Treatment of Multiple Myeloma Related Bone Disease (2008) (5)
- Multiple Myeloma - a New Era of Treatment Strategies (2012) (5)
- Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma. (2021) (5)
- THE CARDIOVASCULAR EFFECTS OF CHIMERIC ANTIGEN RECEPTOR T-CELLS (2019) (5)
- Early MRD negativity to predict deepening myeloma response in relapsed/refractory multiple myeloma (RRMM) patients treated with bb2121 anti-BCMA CAR T cells. (2018) (5)
- MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma. (2014) (5)
- Combination of Nab-Rapamycin and Perifosine Induces Synergistic Cytotoxicity and Antitumor Activity Via Autophagy and Apoptosis in Multiple Myeloma (MM) (2008) (4)
- AZD6244 (ARRY-142886), a Potent and Selective MEK1/2 Inhibitor Blocks the ERK1/2 Signaling Pathway, Inhibits Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications. (2006) (4)
- Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study (2016) (4)
- Cell-free DNA for the detection of emerging treatment failure in relapsed/refractory multiple myeloma (2021) (4)
- Inhibition of the TGF-beta signaling pathway in tumor cells. (2007) (4)
- Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM). (2018) (4)
- The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo (2008) (4)
- Perspectives in the Rapidly Evolving Treatment Landscape of Multiple Myeloma: Expert Review of New Data Presentations from ASH 2019. (2020) (4)
- Digital Health for Patients With Multiple Myeloma: An Unmet Need. (2021) (4)
- Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study (2022) (4)
- Multiple myeloma (1994) (4)
- Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access. (2022) (4)
- Practical considerations and role of Daratumumab retreatment for relapsed refractory Multiple Myeloma (2019) (4)
- Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation (2021) (4)
- Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee (2022) (4)
- Role of Selective HDAC6 Inhibition On Multiple Myeloma Bone Disease (2012) (4)
- Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma (2022) (4)
- A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. (2021) (4)
- Lifestyle considerations in multiple myeloma (2021) (4)
- Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma (2011) (4)
- A phase II, single-arm study of denosumab in multiple myeloma patients with renal insufficiency. (2020) (4)
- A Novel Bruton′s Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity (2013) (4)
- The Treatment of Multiple Myeloma Patients Not Eligible for Asct (2010) (4)
- PS1390 PRELIMINARY DATA: PHASE 1B STUDY OF FEASIBILITY/SAFETY OF ISATUXIMAB SHORT DURATION FIXED VOLUME INFUSION IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (2019) (4)
- TEMPI: A Reversible Syndrome Following Treatment with Bortezomib (2012) (4)
- Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide (2011) (4)
- Mature Osteoblasts Provide a Protective Niche Against Multiple Myeloma Growth and Survival within the Tumor Microenvironment (2018) (4)
- Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1. (2022) (4)
- Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma (2022) (4)
- MM-096: Isatuximab Short-Duration Fixed-Volume Infusion Combination Therapy for Relapsed/Refractory Multiple Myeloma: Final Results of a Phase 1b Feasibility/Safety Study (2020) (4)
- B Cell Lymphoma In Association with Multiple Myeloma: Analysis of the Biologic Relationship (2011) (4)
- ATRAID, a genetic factor that regulates the clinical action of nitrogen-containing bisphosphonates on bone (2018) (3)
- Isatuximab short duration fixed volume infusion combination therapy for relapsed/refractory multiple myeloma (RRMM): phase 1b feasibility/safety study (2019) (3)
- Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma. (2011) (3)
- A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma (2014) (3)
- Disruption of DEPTOR/mTORC1/mTORC2 Signaling Cascade Using a Novel Selective mTOR Kinase Inhibitor AZD8055 Results In Growth Arrest and Apoptosis In Multiple Myeloma Cells (2010) (3)
- Analysis of Hospitalization and Readmissions after CAR T Cell Therapy (2018) (3)
- How We Approach Smoldering Multiple Myeloma (2020) (3)
- FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma (2006) (3)
- Cancer Therapy : Preclinical The Monoclonal Antibody nBT 062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD 138-Positive Multiple Myeloma Cells In vitro and In vivo (2009) (3)
- Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology (2019) (3)
- OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa (2021) (3)
- Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma (2011) (3)
- Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, and Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma (2013) (3)
- Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma (2021) (3)
- Polyunsaturated Fatty Acid (PUFA) Signaling Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma (2019) (3)
- Cancer Therapy : Preclinical In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN 9708 against Multiple Myeloma Cells (2011) (3)
- CAL-101, a Specific Inhibitor of the p110δ Isoform of Phosphatidylinositide 3-Kinase Induces Cytotoxicity in Multiple Myeloma (MM) (2008) (3)
- KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) (2021) (2)
- A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma (2009) (2)
- PF592 IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA (2019) (2)
- Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma (2019) (2)
- Patient Preferences for Multiple Myeloma (MM) Treatment: Interim Analysis of a Discrete Choice Experiment (2018) (2)
- Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study. (2010) (2)
- Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma (2022) (2)
- B483 A Novel Small-Molecule Inhibitor RGB 286638 Induces Apoptosis and Necrosis in Multiple Myeloma (2009) (2)
- Bortezomib induces canonical nuclear factor- (cid:1) B activation in multiple myeloma cells (2009) (2)
- Case 29-2011 (2011) (2)
- Lenalidomide In Combination with the Activin Receptor Type II Murine Fc Protein RAP-011: Preclinical Rationale for a Novel Anti-Myeloma Strategy (2010) (2)
- Pleiotropic activity of the novel cyclin-dependent kinase inhibitor RGB 286638 predicts therapeutic potential in multiple myeloma (2008) (2)
- Conflicts of interest, authorship, and disclosures in industry-related scientific publications. (2010) (2)
- JS-K, a GST-Activated Nitric Oxide Generator, Induces DNA-Double Strand Breaks and Inhibits Growth and Survival of Multiple Myeloma Cells In Vitro and In Vivo. (2006) (2)
- COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia (2021) (2)
- AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity (2010) (2)
- A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone (wKRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM) (2019) (2)
- AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition. (2009) (2)
- Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma. Reply. (2019) (2)
- Lenalidomide and Bortezomib: Targeting Osteoclastogenesis, Osteoclast Survival Factors, and Bone Remodeling Markers in Multiple Myeloma. (2007) (2)
- Real-World Observations and Practical Considerations of Subcutaneous Daratumumab Administration in Multiple Myeloma (2021) (2)
- Treatment Patterns among Patients with Recently-Diagnosed Multiple Myeloma in a National Registry (2008) (2)
- Ethical challenges with multiple myeloma BCMA CAR-T slot allocation: a multi-institution experience. (2023) (2)
- Early Mortality in Newly Diagnosed Multiple Myeloma in the Context of Novel Drugs (2015) (2)
- P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (2022) (2)
- MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM) (2021) (2)
- Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma (2014) (2)
- Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma. (2010) (2)
- HDAC Inhibition in Multiple Myeloma with a Focus on Selective HDAC6 Inhibition (2015) (2)
- The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo. (2008) (2)
- Response with combined modality treatment in childhood rhabdomyosarcoma (1993) (2)
- The Pleiotropic Immunosuppressive Role of Osteoclasts in Multiple Myeloma (2018) (2)
- Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma (2000) (2)
- Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival (2022) (2)
- Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM). (2014) (2)
- Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial (2011) (2)
- Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM). (2015) (2)
- B203 A New Anti-Dkk-1 Antibody Targeting Myeloma Bone Disease (2009) (2)
- Multiple Myeloma Cells Induce Lipolysis in Adipocytes and Uptake Fatty Acids through Fatty Acid Transporter Proteins (2020) (2)
- A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma. (2022) (1)
- A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (2020) (1)
- Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose (2021) (1)
- P-151: Incidence of adverse events in patients with Multiple Myeloma who continued with Denosumab after receiving Denosumab or Zoledronic acid: an open-label extension study (2021) (1)
- OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM) (2021) (1)
- A349 Phase I/II Trial of Perifosine + Bortezomib in Rel/Ref MM Patients Previously Treated with Bortezomib (2009) (1)
- The monoclonal antibody nBT 062 conjugated to maytansinoids has potent and selective cytotoxicity against CD 138 positive multiple myeloma cells in vitro and in vivo (2008) (1)
- Clinical, Radiographic, and Biomarker Characterization of Multiple Myeloma Patients with Bisphosphonate Associated Osteonecrosis of the Jaw. (2006) (1)
- Molecular Profiling of Extramedullary and Medullary Plasmacytomas. (2008) (1)
- Concomitant Suppression of IKZF1, IRF4 and MYC Contribute to the Anti-Tumor Activity of the BET Inhibitor, Cpi-0610, in Disease Models of Multiple Myeloma (2016) (1)
- Serotonin Receptor Antagonists Have an In Vitro and In Vivo Anti-Myeloma Effect That Is Mainly Mediated by Caspase Dependent Apoptosis. (2006) (1)
- The effect of selective inhibition of HDAC6 with ACY1215 on bortezomib activity in multiple myeloma (MM). (2011) (1)
- R-Etodolac and a Novel Indole-Pyran Structural Analog, SDX-308, Induce Cytotoxicity and Overcome Drug Resistance in Multiple Myeloma. (2005) (1)
- Myeloid Derived Suppressor Cells (MDSCs) Regulate Tumor Growth, Immune Response and Regulatory T Cell (Treg) Development in the Multiple Myeloma Bone Marrow Microenvironment (2012) (1)
- B037 CAL-101: A Selective Inhibitor of PI3K p110D for the Treatment of Multiple Myeloma (2009) (1)
- A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41) (2021) (1)
- Magnetismm-4: An Open Label, Phase 1B/2 Umbrella Study of Elranatamab in Combination with Other Anti-Cancer Treatments for Patients with Multiple Myeloma (2022) (1)
- Best of 2017 in Multiple Myeloma (2018) (1)
- 798 Prognostic factors in multiple myeloma (1995) (1)
- 799 VAMP/C-VAMP infusional chemotherapy as induction treatment for previously untreated multiple myeloma (1995) (1)
- 246 Comparison of two stem cell mobilization and harvesting regimens for peripheral blood stem cell (PBSC) transplantation in multiple myeloma (MM) (1995) (1)
- Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease. (2007) (1)
- Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma (2019) (1)
- Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma (2016) (1)
- Inhibition Of Myeloid Derived Suppressor Cells (MDSC) In The Multiple Myeloma Bone Marrow Microenvironment (2013) (1)
- Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study. (2018) (1)
- A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma. (2015) (1)
- Continuous lenalidomide (LEN) therapy versus observation following nonimmunomodulatory compound-based induction therapy in newly diagnosed multiple myeloma (NDMM): MM-027 trial. (2014) (1)
- Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study (2022) (1)
- Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052. (2005) (1)
- Targeting Cyclin D1 in the Treatment of Multiple Myeloma: Preclinical Validation of a Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00. (2006) (1)
- Real-world evidence for carfilzomib dosing intensity on overall survival and treatment progression in multiple myeloma patients. (2021) (1)
- New Clinical and Research Directions in Myeloma-Related Bone Disease (2015) (1)
- JS-K, a GST-Activated Nitric Oxide Generator, Induces Apoptosis and Overcomes In Vitro Drug Resistance in Multiple Myeloma Cells. (2005) (1)
- Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study. (2017) (1)
- Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy (2000) (1)
- Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia (2022) (1)
- Bone Disease in Multiple Myeloma: Biologic and Clinical Implications (2022) (1)
- DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma (2011) (1)
- Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma (2022) (1)
- Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study (2022) (1)
- Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma. (2021) (1)
- BONE MARROW ADIPOSE TISSUE VOLUME INDEPENDENTLY ASSOCIATES WITH ATHEROSCLEROTIC DISEASE BURDEN AND MACE (2020) (1)
- Abstract 2530: Antimyeloma activity of a small molecule multi-targeted kinase inhibitor, AT9283, via potent aurora kinase and STAT3 inhibition (2010) (1)
- Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPE™) for Multiple Myeloma (MM) Digital Solution in Patients with MM (2020) (1)
- The In Vivo Activity of Neutralizing B Cell-Activating Factor (BAFF) Antibody in the Treatment of Multiple Myeloma (MM). (2006) (1)
- Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma (2021) (1)
- Anti-Tumor Activity of a Novel Immunosuppressant FTY720 in Multiple Myeloma. (2004) (1)
- Clinical grade SNaPshot genetic mutation profiling in multiple myeloma. (2014) (1)
- Niche-Based Screening Identifies Novel Small Molecules That Overcome Stromal Effects in Multiple Myeloma (2012) (1)
- Increased Sclerostin Secretion in Multiple Myeloma Plays a Central Role in Osteolytic Bone Disease (2012) (1)
- A randomized, double-blind, multinational trial comparing denosumab with zoledronic acid for treatment of bone disease in adults with newly diagnosed multiple myeloma. (2014) (1)
- The research mission in myeloma (2009) (1)
- Updates to the NCCN Guidelines (2013) (1)
- Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM). (2009) (1)
- Endothelial Cells Induce Multiple Myeloma Cell Proliferation Protect Against Conventional and Novel Therapies. (2004) (1)
- MLN 120 B , a Novel I K BKinase B Inhibitor , Blocks Multiple Myeloma Cell Growth In vitro and In vivo (2006) (1)
- Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma: Current Phase I/II Combinations (2009) (1)
- Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma (2018) (1)
- Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study (2021) (1)
- Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma (2022) (1)
- Advances in Brief Functional Interaction between Retinoblastoma Protein and Stress-activated Protein Kinase in Multiple Myeloma Cells 1 (1999) (1)
- CYC065, a Potent Derivative of Seliciclib Is Active In Multiple Myeloma In Preclinical Studies (2010) (1)
- New Treatments for Optimizing Bone Health in Patients With Multiple Myeloma: Proceedings From the Symposium Held at the IX International Meeting on Cancer-Induced Bone Disease (2010) (1)
- Novel In Vivo Model of Multiple Myeloma Bone Disease Using ß-Tricalcium Phosphate Artificial Bone Grafts (2015) (1)
- The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma (2013) (1)
- A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial) (2022) (1)
- Giving voice to patients: Understanding treatment preferences of patients with multiple myeloma (MM). (2019) (1)
- The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM). (2005) (1)
- Is Upfront Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma the Standard (2017) (1)
- 620O CART-ddBCMA for multiple myeloma: Interim results from phase I study (2022) (1)
- Osteoclast Activation in Multiple Myeloma (2010) (1)
- Denosumab Compared with Zoledronic Acid for Preventing Skeletal Complications in Patients with Multiple Myeloma: A Randomized, Phase 3, Double-Blind, Double-Dummy Trial (2012) (1)
- Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study. (2021) (1)
- Denosumab compared with zoledronic acid for the treatment of bone disease in adults with newly diagnosed multiple myeloma: An international, randomized, double-blind trial. (2015) (1)
- Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study (2019) (1)
- Do We Need Another HDAC Inhibitor in Multiple Myeloma (2015) (1)
- Twice-weekly Ixazomib plus Lenalidomide-dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-term Follow-up Data for Patients Not Undergoing Stem Cell Transplantation (SCT) (2017) (1)
- Interactions of the Mdm2/p53 and Proteasome Pathways: Implications for Combination Strategies to Enhance the Anti-Myeloma Activity of Bortezomib (2008) (1)
- 1 JSK , a GST-activated nitric oxide generator , induces DNA double strand breaks , activates DNA damage response pathways , and induces apoptosis in vitro and in vivo in human multiple myeloma cells (2007) (1)
- Effect of the specific P53 stabilizer CBS9106 on multiple myeloma (MM). (2016) (1)
- Bortezomib Targets Multiple Myeloma Endothelial Cells. (2004) (1)
- Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network (2022) (1)
- Inhibition of Histone Deacetylase 6 Effects on Interaction of Tumor and Immune Cells In Multiple Myeloma (2010) (1)
- Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis (2011) (1)
- Evolving Areas of Consensus and Disagreement Among Experts in Treatment of Patients with Multiple Myeloma (MM) (2018) (0)
- apoptosis myeloma by induction of caspase-dependent and -independent Honokiol overcomes conventional drug resistance in human multiple (2010) (0)
- Minimal resid ual dis ease in mul ti ple mye loma : why , when , where (2021) (0)
- P968: ADDITION OF IXAZOMIB TO POMALIDOMIDE AND DEXAMETHASONE IMPROVES PROGRESSION-FREE SURVIVAL FOR MULTIPLE MYELOMA PATIENTS PROGRESSING ON LENALIDOMIDE AS PART OF 1ST LINE THERAPY: ALLIANCE A061202 (2022) (0)
- Case 27-2001: Waldenstrom's macroglobulinemia. (2002) (0)
- Overcoming MCL1 Resistance in Multiple Myeloma (2018) (0)
- [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth In vitro and in vivo activity of atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro (2005) (0)
- Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA (2021) (0)
- Infectious Complications in Patients Following B-Cell Maturation Antigen: Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (2023) (0)
- Title: Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients (2013) (0)
- SDX-101 Is Cytotoxic and Overcomes Drug Resistance in Multiple Myeloma. (2004) (0)
- Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment. (2004) (0)
- Targeting Src-family kinase activation and downstream molecular events to overcome MM cell growth, survival, and drug-resistance. (2005) (0)
- The Role of Novel Therapies in Myeloma Patients with Renal Insufficiency (2012) (0)
- Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma (2019) (0)
- The Biologic Relevance of PIM Kinases in the Context of Multiple Myeloma and Their Potential As Therapeutic Targets in Combination Drug Therapy (2015) (0)
- Cancer Therapy: Preclinical In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells (2011) (0)
- Identification and Validation of HLA-A24 XBP1us, XBP1sp, CD138, and CS1 Peptides to Generate Antigens Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other Cancers (2016) (0)
- A CASE OF VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE, CHRONIC LUNG DISEASE, AND RECURRENT INFECTIONS (2018) (0)
- specific cytotoxic T lymphocytes - Ex vivo induction of multiple myeloma (2013) (0)
- Genetic Predisposition for Medication-Related Osteonecrosis of the Jaws: A Systematic Review (2019) (0)
- Inhibition of fatty acid synthase induces anti-tumor effect in multiple myeloma (2008) (0)
- Bone Marrow Adipocytes Induce Metabolic Reprogramming of Multiple Myeloma Cells (2021) (0)
- OAB-029: Bone marrow adipocytes induce metabolic reprogramming of multiple myeloma cells (2021) (0)
- PreclinicalActivityoftheOralProteasomeInhibitorMLN9708 in Myeloma Bone Disease (2014) (0)
- Molecular Sequaele of Activin A-Dependent Osteoblast Inhibition in Myeloma. (2009) (0)
- Anemia and Erythropoeitic Growth Factors in Multiple Myeloma (2008) (0)
- Multiple Myeloma Cell-Osteoblast Interaction Results in Impaired Bone Formation. (2007) (0)
- The Role of the Bone Marrow Microenvironment in the Pathogenesis of Multiple Myeloma (2007) (0)
- Use of Alkylating Agents Among Patients with Multiple Myeloma in a National Registry, 2006-2008. (2009) (0)
- Induction of Apoptosis by Didox Via Down-Regulation of Bcl-2 Family Proteins in Multiple Myeloma (MM). (2004) (0)
- Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma (2021) (0)
- Erratum (2006) (0)
- PF612 ONCE-WEEKLY (70 MG/M2) VERSUS TWICE-WEEKLY (56 MG/M2) DOSING OF CARFILZOMIB FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (2019) (0)
- Novel Bone-Targeting Agents in Multiple Myeloma (2009) (0)
- Epigenetic modulation by VidazaTM induces apoptosis and overcomes in vitro drug resistance in human multiple myeloma cells. (2007) (0)
- Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy (2023) (0)
- Evolving therapies for multiple myeloma (2011) (0)
- OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study (2021) (0)
- Other Plasma Cell Dyscrasias (2003) (0)
- Leaving Lytic Lesions-Is There New Role for Radiation in Multiple Myeloma in the CAR T Era? (2022) (0)
- Association of high baseline ferritin with tocilizumab administration for CRS in relapsed/refractory multiple myeloma patients treated with bb2121 anti-BCMA CAR T cells. (2018) (0)
- Determining Resistance Mechanisms in BRAF-mutated Multiple Myeloma (2019) (0)
- VEGF Upregulates Mcl-1 Expression and Protects Multiple Myeloma Cells Against Starvation Induced-Apoptosis. (2004) (0)
- CCR1 Inhibition Targets Osteoclast-Myeloma Adhesion and Exerts in Vivo Anti-Osteoclast Activity (2008) (0)
- Peripheral Blood Genomic Interrogation in Myeloma: Developing a Blood Biopsy to Replace the Bone Marrow Biopsy (2017) (0)
- Overcoming p53 Loss with a Multi-Targeted Small Molecule Inhibitor in Multiple Myeloma. (2009) (0)
- IN THE SPOTLIGHT Targeting BRAF in Multiple Myeloma (2013) (0)
- Role of Salvage Autologous Transplant in Multiple Myeloma (2016) (0)
- 797 Single centre results of therapy including autografts in previously untreated myeloma (1995) (0)
- P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3 (2022) (0)
- Multiple myeloma (2001) (0)
- MicroRNA expression patterns in medullary and extramedullary plasmacytoma (2014) (0)
- MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM) (2021) (0)
- Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting (2018) (0)
- Comparison of Skeletal Complications and Treatment Patterns Associated with Early Versus Delayed Zoledronic Acid Therapy In Multiple Myeloma (2010) (0)
- cells in the multiple myeloma microenvironment in humans Tumor-promoting immune-suppressive myeloid-derived suppressor (2013) (0)
- AUTOINFLAMMATORY DISORDER IN A PEDIATRIC PATIENT (2018) (0)
- Combining PD-1 Inhibition With Pemalidomide for Relapsed/Refractory Multiple Myeloma (2017) (0)
- Epigenetic Modulation by Vidaza™ induces Apoptosis and Overcomes In Vitro Drug Resistance in Human Multiple Myeloma Cells. (2006) (0)
- New Developments in Multiple Myeloma (2014) (0)
- Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial (2021) (0)
- Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs (2008) (0)
- Cancer Therapy : Preclinical Preclinical Activity of theOral Proteasome InhibitorMLN 9708 in Myeloma Bone Disease (2014) (0)
- Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop. (2023) (0)
- Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications. (2007) (0)
- P-042: Phase 1 dose-escalation study of sotatercept in combination with lenalidomide and dexamethasone or pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (2022) (0)
- Pomalidomide for the treatment of relapsed and refractory multiple myeloma (2014) (0)
- Current & Emerging Therapeutics for Multiple Myeloma (2013) (0)
- Defining the differentiation states of multiple myeloma at single cell resolution – Identifying opportunities for immunotherapy (2019) (0)
- Panobinostat and Multiple Myeloma in 2018 The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters (2018) (0)
- Comparison of Denosumab Versus Intravenous (IV) Bisphosphonate Use for Hypercalcemia in Multiple Myeloma (2020) (0)
- Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells. (2006) (0)
- Targeting Glycolysis and Compensatory Mitochondrial Metabolism In An In Vivo Xenograft Model Of Multiple Myeloma With FDA Approved Ritonavir and Metformin (2013) (0)
- P-150: Quality of life, psychological distress, and prognostic awareness in patients with Multiple Myeloma (2021) (0)
- P209 Hypereosinophilic syndrome presenting as acute necrotizing eosinophilic myocarditis: a case of rapid improvement with corticosteroids (2016) (0)
- Upregulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma and other malignancies (2007) (0)
- P-065: CyTOF and single cell RNA sequencing reveal altered T cell phenotypes in Multiple Myeloma patients: implications for immunotherapy (2021) (0)
- Abstract 14967: Cardiac Toxicity and Cardiovascular Events Among Adult Patients Treated With Chimeric Antigen Receptor T-Cells: A Multi-Center Registry (2019) (0)
- Assessment of Knowledge and Performance Gaps in the Treatment of Patients with Multiple Myeloma (2010) (0)
- Perceptions of prognosis in caregivers of multiple myeloma (MM) patients. (2021) (0)
- B469 Unraveling the Synergism of Nab-Rapamycin and Perifosine Combination in Multiple Myeloma (2009) (0)
- Multiple myeloma. (2000) (0)
- Upregulation of c-Jun Induces Cell Death Via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma. (2006) (0)
- Novel Drugs Push the Envelope in Multiple Myeloma (2016) (0)
- BIRB796 Inhibits p38 MAPK/Hsp27 Pathway and Enhances Cytotoxicity Triggered by Bortezomib, Hsp90 Inhibitor, and Dexamethasone in Multiple Myeloma. (2006) (0)
- In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase Inhibitor, CYC202 (seliciclib or R-Roscovitine), in Multiple Myeloma (MM). (2004) (0)
- Attitudes toward Participation in Research, New Treatments, and Medication Side Effects among Multiple Myeloma and Myelodysplastic Syndrome Patients - The Patient Registries at Slone: Myeloma & MDS. (2007) (0)
- P192 Recurrent HSV-1 infection in an infant secondary to a TLR-3 defect (2016) (0)
- P-107: NCOR2 mediated MYC upregulation drives drug resistance in multiple myeloma independent of Cereblon (2021) (0)
- Treatment Strategy for Relapse and Refractory Multiple Myeloma and Role of Pomalidomide (2019) (0)
- OAB-007: Updated clinical and correlative results from the Phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and/or refractory multiple myeloma (2022) (0)
- Nivolumab-Based Salvage Therapy to Restore T Cell Fitness in Penta-Refractory Multiple Myeloma with Relapse to Anti-BCMA CAR T Cell Therapy (2022) (0)
- RECURRENT AND CYCLIC FEVERS IN A PEDIATRIC PATIENT (2018) (0)
- synergistic activity in multiple myeloma Combination of the mTOR inhibitor rapamycin and CC-5013 has (2013) (0)
- B457 AT7519, a Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma via GSK3B (2009) (0)
- Reply to the Letter to the Editor from Noopur Raje and Kenneth C. Anderson (2008) (0)
- multiple myeloma cell lines CD40 activation mediates p53-dependent cell cycle regulation in human (2008) (0)
- Molecular Features and Clinical Outcomes of Extramedullary Plasmacytomas (2021) (0)
- OAB-053: Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (2022) (0)
- Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma (2010) (0)
- Updates and rationale of clinical trials in multiple myeloma (2019) (0)
- Role of Osteoblast in Myeloma Pathology (2013) (0)
- New immune modulators (2013) (0)
- Molecular Characterization of PS-341 (bortezomib) Resistance: Implications for Overcoming Resistance Using Lysophosphatidic Acid Acyltransferase (LPAAT)-β Inhibitors. (2004) (0)
- Detection of Kaposi's Sarcoma Herpesvirus Gene Sequences Multiple Myeloma Are Phenotypically and Functionally Normal Despite the Bone Marrow and Peripheral Blood Dendritic Cells From Patients With (2008) (0)
- CCL3 Impairs Osteoblast Function Via Downregulation of Osteocalcin. (2009) (0)
- Effect of the Pan-PIM Kinase Inhibitor, AZD1208, Alone and in Combination with Bortezomib in Multiple Myeloma (2014) (0)
- Role of Sclerostin in Multiple Myeloma Progression (2017) (0)
- Diagnostic Advances in Multiple Myeloma: The Role of Magnetic Resonance Imaging (2015) (0)
- Chimeric Antigen Receptor T Cells for the Treatment of Multiple Myeloma (2016) (0)
- Transitioning to an All Oral Therapy for Multiple Myeloma with the Novel Proteasome Inhibitor Ixazomib (2015) (0)
- Carbon-11-Labelled Methionine PET/CT in Patients With FDG-Occult Multiple Myeloma: A Prospective Pilot Study. (2022) (0)
- Checking Multiple Myeloma with Pembrolizumab (2016) (0)
- Combinational Therapy of Lenalidomide with Activin A Neutralizing Antibody; Preclinical Rationale for a Novel Anti-Myeloma Strategy (2012) (0)
- Where is the “Attention Deficit” in ADHD? Perspectives from Cognitive Neuroscience and Recommendations for Future Research (2007) (0)
- against apoptosis VEGF induces MCL-1 upregulation and protects multiple myeloma cells (2013) (0)
- Immunomodulatory Effects of Histone Deacetylase 6 Inhibition in Suppressor Immune Cells in Multiple Myeloma (2011) (0)
- Once-weekly (70 mg/m2) versus twice-weekly (56 mg/m2) dosing of carfilzomib (CFZ) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM). (2019) (0)
- 801 Second autografts for relapsed myeloma (1995) (0)
- The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development (2011) (0)
- High dose of Zoledronic acid inhibits both osteoclasts and osteoblasts in an In Vivo mouse model (2008) (0)
- Mature Osteoblasts Are Critical Bone Marrow Niche Cells Regulating Multiple Myeloma Cell Growth, at Least in Part, By Affecting the Local Immune Microenvironment (2021) (0)
- The Etiology and Pathophysiology of Multiple Myeloma (2010) (0)
- Monoclonal Antibodies in the Treatment of Multiple Myeloma with a Focus on Elotuzumab and Daratumumab (2015) (0)
- Multiple myeloma gammopathies BCL 2 blockade overcomes MCL 1 resistance in multiple myeloma (2019) (0)
- B281 Ciliary Proteins and Hedgehog Pathway in Multiple Myeloma (2009) (0)
- B357 Targeting Myeloma Bone Disease via Activin A Inhibition (2009) (0)
- Anti-Myeloma Activity of Two Novel N-Substituted and Tetraflourinated Thalidomide Analogues. (2004) (0)
- Combining Daratumumab With Backbone Antimyeloma Agents (2016) (0)
- A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (2021) (0)
- Evaluating efficiency of bone marrow harvest and its manipulation--role of CD 34 positivity. (1995) (0)
- Didox Induced Apoptosis Occurs by Inhibiting DNA Synthesis and Repair Via Down-Regulation of Ribonucleotide Reductase M1 in Multiple Myeloma (MM). (2005) (0)
- M287 AN ATYPICAL PRESENTATION OF STAT3 HYPER-IGE SYNDROME (2019) (0)
- A Novel in-Vivo Model to Examine Homing of Multiple Myeloma Cells in Postnatal, Inducible, and Reversible Loss of Mature Osteoblasts (2020) (0)
- From cell biology to therapy: lenalidomide in relapsed/refractory multiple myeloma (2009) (0)
- 17 – Multiple Myeloma and Plasma Cell Dyscrasias (2010) (0)
- NCOR2 Mutations Are Associated with IMiD Resistance in Human Myeloma Cells (2020) (0)
- MRD Detection Testing to Study Clonal Selection and Drug Resistance (2016) (0)
- Mature Osteoblasts Promote Multiple Myeloma Survival through Cell-Cell Contact and Immune Modulation Mechanisms (2019) (0)
- the Use of Tailored Feedback to Improve Hematologist Competence and Clinical Decision Making for the Treatment of Patients with Multiple Myeloma: a Novel Web-Based Educational Solution (2016) (0)
- p38MAPK Inhibitor LSN2322600 Modulates the Bone Marrow Microenvironment and Inhibits Osteoclastogenesis in Multiple Myeloma. (2006) (0)
- My COVID-19 experience (2020) (0)
- The Tyrosine Kinase Inhibitor Adaphostin (NSC 680410), but Not Imatinib Mesylate, Inhibits Survival and Src Tyrosine Kinase Family- Triggered Signaling Pathways of MM Cells. (2004) (0)
- The TEMPI Syndrome: Telangiectasias, Elevated Erythropoietin and Erythrocytosis, Monoclonal Gammopathy, Perinephric Fluid Collections, and Intrapulmonary Shunting (2011) (0)
- Myeloma Bone Marrow Stromal Cells Detection of Kaposi's Sarcoma Herpesvirus DNA Sequences in Multiple (2013) (0)
- Role of BAFF in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment. (2005) (0)
- Hypogammaglobulinemia and Risk of Infectious Complications in Patients Receiving Idecabtagene vicleucel (2023) (0)
- Table 136-3, Classification of Monoclonal Gammopathies (2003) (0)
- Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis (2022) (0)
- Increased Sensitivity to DNA Damage Multiple Myeloma Cells Is Associated with Ku86 Variant Expression and Function in (2013) (0)
- P-134: Quality of life, psychological distress, and prognostic awareness in caregivers of patients with Multiple Myeloma (2021) (0)
- NPI-2358, a Novel Vascular Disrupting Agent Blocks Growth and Angiogenesis in Multiple Myeloma Cells. (2009) (0)
- P-282: Addition of ixazomib to pomalidomide-dexamethasone improves progression-free survival for myeloma patients progressing on frontline lenalidomide: results of the randomized alliance study A061202 (2022) (0)
- OAB-012: Early and sustained negative minimal residual disease (MRDneg) after idecabtagene vicleucel (ide-cel) defines a subset of multiple myeloma (MM) patients in KarMMa achieving prolonged survival (2022) (0)
- Effect of the Wnt-Signaling Inhibitor Sclerostin and Bone Marrow Adipocytes on Multiple Myeloma (2016) (0)
- MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation. (2006) (0)
- Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma (2012) (0)
- Practice-Changing Daratumumab Combinations for the Treatment of Multiple Myeloma (2017) (0)
- Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy (2019) (0)
- Bcl-2, Mcl-1 and p53 Expression Confer Sensitivity to Bcl-2 Inhibitor ABT-737 in Multiple Myeloma. (2006) (0)
- Treatment of Patients in First or Second Relapse (2018) (0)
- myeloma interaction of tumor and bone marrow accessory cells in multiple Immunomodulatory effects of lenalidomide and pomalidomide on (2012) (0)
- Novel Etodolac Analog SDX-308 (CEP-18082) Induces Cytotoxicity in Multiple Myeloma Cells Associated with Inhibition of Wnt/β-Catenin Pathway. (2006) (0)
- MLN120B, a Novel IKBKinase B Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo (2006) (0)
- Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma (2021) (0)
- 814 Peripheral blood transplants followed by maintenance interferon in myeloma (1995) (0)
- Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma. (2007) (0)
- Analysis of Healthcare Professional Management of CAR T-Cell Toxicities and Concordance with Expert Consensus Recommendations (2022) (0)
- OAB-003: Phase 1 study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain for the treatment of subjects with relapsed and refractory multiple myeloma (2022) (0)
- Mutational Profiling of Multiple Myeloma Bone Marrow Aspirates As a Clinical Tool for Personalized Treatment of Myeloma (2012) (0)
- Extending Dosing Intervals of Denosumab As a Maintenance Strategy in Multiple Myeloma: A Real-World Experience at a Large Academic Cancer Center (2020) (0)
- The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG) (2019) (0)
- Rhabdomyosarcoma in children :clinical features and results of an aggressive chemotherapy regimen. (1996) (0)
- Inhibition of Hsp90 Targets Multiple Myeloma Cell Growth, Angiogenesis, and Osteoclastogenesis in the BM Microenvironment. (2007) (0)
- Small Molecule Therapeutics Delineating themTORKinasePathwayUsingaDual TORC 1 / 2 Inhibitor , AZD 8055 , in Multiple Myeloma (2014) (0)
- Dietary Supplement Vitamin C Significantly Abrogates Bortezomib-Induced Multiple Myeloma (MM) Cell Growth Inhibition (2008) (0)
- by Dexamethasone Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced (2013) (0)
- Circulating tumor DNA in the peripheral blood as early predictor of clinical outcome in relapsed/ refractory multiple myeloma (2019) (0)
- Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells. (2006) (0)
- P270 An expanding spectrum of autoinflammatory syndromes: TNFAIP3-related disease (2017) (0)
- In Vivo Effects of Zoledronic Acid on Bone Remodeling. (2007) (0)
- AVL-292, a Bruton's Tyrosine Kinase Inhibitor Impacts Bone Resorption by Abrogating Osteoclast Sealing Zone Formation in Multiple Myeloma (2012) (0)
- CYC202 (seliciclib or R-Roscovitine), a small molecule cyclin dependent kinase inhibitor, overcomes drug resistance via down-regulation of Mcl-1 in multiple myeloma (MM) (2005) (0)
- Programming Myeloma Cell Death With Venetoclax (2017) (0)
- OAB-045: COVID-19 vaccine responsiveness in patients with Multiple Myeloma and Waldenström Macroglobulinemia (2021) (0)
- 1553TiPCOMPARISON OF DENOSUMAB VS ZOLEDRONIC ACID FOR TREATMENT OF BONE DISEASE IN ADULTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A RANDOMIZED, DOUBLE-BLIND, MULTINATIONAL PHASE 3 TRIAL. (2014) (0)
- Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma. (2007) (0)
- A227 Lenalidomide, Bortezomib, and Dexamethasone Is Active in High-Risk Relapsed/Refractory Myeloma (2009) (0)
- P-002: Real-world observations and practical considerations of subcutaneous daratumumab administration in multiple myeloma (2021) (0)
- CCR1 Inhibition Impairs Osteoclast Activity and Interaction with Myeloma Cells. (2006) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Noopur S. Raje?
Noopur S. Raje is affiliated with the following schools: